MedPath

Recommendations for Monitoring Clinical Experience Following Implantation of the AcrySof® Toric

Phase 4
Withdrawn
Conditions
Cataract
Interventions
Device: AcrySof® Toric IOL
Registration Number
NCT00761488
Lead Sponsor
Alcon Research
Brief Summary

To allow surgeons to obtain clinical experience on the postoperative uncorrected and best distance corrected visual acuities (UCVA and BDCVA) and corneal and refractive cylinder of the AcrySof Toric IOL.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • 40-80 years old; of any race and gender; diagnosed with bilateral cataracts; require cataract extraction followed by implantation of a posterior chamber IOL; patients have between 0.75 -2.5 D of astigmatism preoperatively as measured by K readings.
Exclusion Criteria
  • Females of child bearing potential;irregular corneal astigmatism;keratopathy/Keratectasia; cornea inflammation or edema;previous corneal reshaping,dystrophy or transplant;amblyopia;glaucoma;RPE/Macular changes;diabetic retinopathy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
1AcrySof® Toric IOLAcrySof® Toric IOL
Primary Outcome Measures
NameTimeMethod
Corneal astigmatism; IOL rotationBefore opertation; 1 day following implantation of each eye; 1, 3 months following lens implantation in the second eye.
Secondary Outcome Measures
NameTimeMethod
Uncorrected and best distance corrected visual acuities (UCVA and BDCVA)Before opertation; 1 day following implantation of each eye; 1, 3 months following lens implantation in the second eye.

Trial Locations

Locations (1)

Alcon Call Center

🇺🇸

Fort Worth, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath